Breast Cancer Liquid Biopsy Market Size, Share, Growth Analysis, By Technology(Next-generation sequencing (NGS), polymerase chain reaction (PCR), and other techniques), By Biomarker(Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs)), By End user(Hospitals, diagnostic laboratories, and research centers), By Region - Industry Forecast 2024-2031

Breast Cancer Liquid Biopsy Market size was valued at USD 277 million in 2021 and is poised to grow from USD 417.03 million in 2023 to USD 1746.15 million by 2030, at a CAGR of 22.7% during the forecast period (2023-2030).

The breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth. 'Guardant Health - United States', 'Roche Diagnostics - Switzerland', 'Biocept, Inc. - United States', 'Genomic Health (acquired by Exact Sciences) - United States', 'Illumina, Inc. - United States', 'Thermo Fisher Scientific - United States', 'QIAGEN - Germany', 'Myriad Genetics - United States', 'Personal Genome Diagnostics Inc. (PGDx) - United States', 'Bio-Rad Laboratories, Inc. - United States', 'Trovagene, Inc. (acquired by Admera Health) - United States', 'Exosome Diagnostics (acquired by Bio-Techne Corporation) - United States', 'Sysmex Corporation - Japan', 'Natera, Inc. - United States', 'Foundation Medicine (acquired by Roche) - United States', 'GRAIL, Inc. (acquired by Illumina) - United States', 'Menarini Silicon Biosystems - Italy', 'Angle plc - United Kingdom', 'Cynvenio Biosystems, Inc. - United States', 'DiaCarta, Inc. - United States'

The increasing adoption of liquid biopsy techniques is a significant driver in the breast cancer liquid biopsy market. Compared to traditional tissue biopsies, liquid biopsies allow for the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers present in blood samples, enabling healthcare professionals to make more informed treatment decisions. Additionally, liquid biopsy has the potential to identify resistance mutations and minimal residual disease, which can aid in personalized treatment strategies, leading to improved patient outcomes and reduced healthcare costs.

There was a growing emphasis on non-invasive diagnostic methods, such as liquid biopsies, for early detection and monitoring of breast cancer.

North America led the way with a strong presence of key market players, advanced healthcare infrastructure, and growing adoption of liquid biopsy technologies. Europe demonstrated significant growth due to increased awareness, supportive government initiatives, and rising research and development activities. The Asia-Pacific region exhibited substantial potential, driven by a large patient pool, expanding healthcare expenditure, and increasing focus on personalized medicine. Latin America and the Middle East/Africa regions also experienced a gradual uptick in liquid biopsy adoption, with improving healthcare facilities and a greater emphasis on cancer diagnostics.